Li MY, Li TT, Li KJ, Zhou C. Type 2 diabetes mellitus characteristics affect hepatocellular carcinoma development in chronic hepatitis B patients with cirrhosis. World J Clin Cases 2023; 11(5): 1009-1018 [PMID: 36874430 DOI: 10.12998/wjcc.v11.i5.1009]
Corresponding Author of This Article
Man-Yu Li, PhD, Assistant Professor, Research Assistant Professor, Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, No. 2 Tiantanxili Road, Dongcheng District, Beijing 100050, China. myli226@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 16, 2023; 11(5): 1009-1018 Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1009
Type 2 diabetes mellitus characteristics affect hepatocellular carcinoma development in chronic hepatitis B patients with cirrhosis
Man-Yu Li, Ting-Ting Li, Ke-Jian Li, Cheng Zhou
Man-Yu Li, Ke-Jian Li, Cheng Zhou, Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing 100050, China
Ting-Ting Li, Department of Clinical Laboratory, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Author contributions: Li MY designed and performed the research and wrote the paper; Li TT designed the research and contributed to the analysis; Li KJ and Zhou C supervised the report.
Supported bythe National Institutes for Food and Drug Control, No. 2022C4.
Institutional review board statement: This study was reviewed and approved by the Human Ethics Committee of the Fifth Affiliated Hospital of Zhengzhou University (KY2021031).
Informed consent statement: Patients were not required to give informed consent for the study because the analysis used anonymous clinical data that were approved by the Human Ethics Committee of the Fifth Affiliated Hospital of Zhengzhou University.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Man-Yu Li, PhD, Assistant Professor, Research Assistant Professor, Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, No. 2 Tiantanxili Road, Dongcheng District, Beijing 100050, China. myli226@163.com
Received: October 31, 2022 Peer-review started: October 31, 2022 First decision: November 11, 2022 Revised: November 24, 2022 Accepted: January 16, 2023 Article in press: January 16, 2023 Published online: February 16, 2023 Processing time: 106 Days and 0.2 Hours
ARTICLE HIGHLIGHTS
Research background
Type 2 diabetes mellitus (T2DM) has been shown to be correlated with hepatocellular carcinoma (HCC) development. However, the T2DM characteristics that affect HCC are unknown.
Research motivation
T2DM affects more than 440 million individuals globally. T2DM is a leading cause of death due to renal and heart complications as well as an increased risk of multiple cancers. Understanding the correlation between T2DM and HCC will benefit these patients.
Research objectives
This study aimed to investigate the relationship between T2DM clinical characteristics and HCC development in pre-existing T2DM patients with chronic hepatitis B (CHB).
Research methods
Among 412 CHB patients enrolled in this study, there were 196 patients with T2DM. The patients were divided into the T2DM group and the non-T2DM group (n = 216). Clinical characteristics and outcomes of the two groups were compared.
Research results
T2DM was found to be significantly related to hepatocarcinogenesis in this study. In the multivariate analysis, T2DM, male sex, alcohol abuse status, alpha-fetoprotein (AFP) > 20 ng/mL, and hepatitis B surface antigen (HBsAg) > 2.0 log IU/mL were identifeid to be risk factors for HCC development. T2DM duration and therapy significantly increased the risk of hepatocarcinogenesis.
Research conclusions
T2DM was found to be related to a poor CHB prognosis. Male sex, alcohol abuse status, AFP > 20 ng/mL and HBsAg > 2.0 log IU/mL were also significantly related with poor outcomes. T2DM characteristics, including T2DM duration more than 5 years and treatment of diet control or insulin ± sulfonylurea significantly increased the risk of hepatocarcinogenesis.
Research perspectives
These findings confirmed the importance of diabetic management in CHB patients. The exact mechanism of how T2DM affects HCC development still warrants further study.
